利福昔明联合乳果糖治疗肝性脑病患者疗效及其血清S100B蛋白和神经元特异性烯醇化酶变化

doi:10.3969/j.issn.1672-5069.2021.01.027

摘要/Abstract

摘要： 目的探讨应用利福昔明联合乳果糖治疗肝性脑病(HE)患者的疗效及其血清S100B蛋白和神经元特异性烯醇化酶(NSE)水平的变化。方法 2015年6月~2019年6月我院收治的失代偿期乙型肝炎肝硬化并发HE患者74例,随机分为观察组37例和对照组37例。在内科治疗的基础上,给予对照组乳果糖口服,给予观察组乳果糖联合利福昔明治疗,两组均治疗1周。采用ELISA法检测血清C-反应蛋白(CRP)、肿瘤坏死因子-(TNF-)和白介素-6(IL-6),采用电化学发光法检测血清S100B蛋白、NSE和血浆β-内啡肽 (β-EP)水平,常规检测血氨。应用数字连接试验(NCT)和数字符号试验(DS)评价认知功能。结果观察组生存率为83.8%,显著高于对照组的62.1%(P<0.05);治疗后,观察组31例生存患者血清CRP水平为(14.9±3.5)mg/L,显著低于23例对照组【(17.4±3.8)mg/L,P<0.05】,血清TNF-α水平为(12.3±3.8)ng/L,显著低于对照组【(15.3±4.4)ng/L,P<0.05】,血清IL-8水平为(35.8±7.5)pg/mL,显著低于对照组【(41.5±9.8)ng/L,P<0.05】,血清S100B蛋白水平为(27.4±13.1)ng/L,显著低于对照组【(38.7±14.0)ng/L,P<0.05】,血清NSE水平为(14.6±6.4)μg/L,显著低于对照组【(19.4±8.3)μg/L,P<0.05】,血浆β-EP水平为(46.7±5.3)pg/mL,显著低于对照组【(52.8±6.7)pg/mL,P<0.05】;血清丙氨酸氨基转移酶(ALT)水平为(67.3±16.1)U/L,显著低于对照组【(92.5±21.8)U/L,P<0.05】,而血清白蛋白(ALB)水平为(35.3±7.1)g/L,显著高于对照组【(32.7±6.8)g/L,P<0.05】,血氨水平为(61.7±11.4)μmol/L,显著低于对照组【(98.1±13.3)μmol/L,P<0.05】; NCT时间为(54.3±8.5)s,显著短于对照组【(69.7±10.8)s,P<0.05】,而DS评分为(58.5±7.2)分,显著高于对照组【(47.3±8.9)分,P<0.05】。结论应用利福昔明联合乳果糖治疗肝硬化引起的HE患者可有效抑制炎症反应,改善肝功能,减轻神经系统功能损伤,降低血氨、血清S100B蛋白和NSE水平,提高认知功能,疗效较好。

关键词: 肝硬化, 肝性脑病, 利福昔明, 乳果糖, 认知功能, 治疗

Abstract: Objective The aim of this study was to investigate combination of rifaximin and lactulose in dealing with hepatitis B cirrhotic patients with hepatic encephalopathy (HE) and observe its clinical efficacy and mortality. Methods 74 patients with HE were admitted to our hospital between June 2015 and June 2019, and were randomly divided into two groups, with 37 cases in each. 37 patients were treated with lactulose and another 37 with lactulose and rifaximin combination for seven days. Serum S100B protein, neuron-specific enolase (NSE), C-reactive protein (CRP), tumor necrosis factor-α (TNF-), interleukin-8 (IL-8) and β-endorphin,β-EP) were assayed, and number connection test (NCT) and digital symbol test (DS) were applied for evaluation of cognition. Results The survival rate in combination group was 83.8%, significantlyhigher than 62.1% in lactulose-treated group (P<0.05); after treatment, serum CRP level in the combination group was (14.9±3.5) mg/L, much lower than , serum TNF-α level was (12.3±3.8) ng/L, significantly lower than , serum IL-8 level was (35.8±7.5) pg/mL significantly lower than , serum S100B protein level was (27.4±13.1) ng/L, significantly lower than , serum NSE level was (14.6±6.4) μg/L, significantly lower than , and plasma β-EP level was (46.7±5.3) pg/mL, significantly lower than in lactulose-treated group; serum alanine aminotransferase (ALT) level was (67.3±16.1) U/L, significantly lower than , while serum albumin (ALB) level was (35.3±7.1)g/l, significantly higher than in lactulose-treated group; the blood ammonia level was (61.7 1±1.4) μmol/L, significantly lower than in lactulose-treated group; the time of NCT was (54.3± 8.5) s, which was much shorter than , and the DS score was (58.5 ±7.2), which was significantly higher than in lactulose-treated group.Conclusion The combination of rifaximin and lactulose in the treatment of cirrhotic patients with HE could effectively inhibit the inflammatory reaction, improve liver functions, reduce stress injury, and improve cognitive functions, which might correlated to the reduction of serum S100B protein and NSE levles, and is worthy of further clinical research.

Key words: Liver cirrhosis, Hepatic encephalopathy, Rifaximin, Lactulose, Cognitive functions, Therapy

范静, 徐静, 袁雪. 利福昔明联合乳果糖治疗肝性脑病患者疗效及其血清S100B蛋白和神经元特异性烯醇化酶变化[J]. 实用肝脏病杂志, 2021, 24(1): 103-106.

Fan Jing, Xu Jing, Yuan Xue. Combination of rifaximin and lactulose improves clinical efficacy and mortality in hepatitis B cirrhotic patients with hepatic encephalopathy[J]. Journal of Practical Hepatology, 2021, 24(1): 103-106.

参考文献

[1] Hadjihambi A, Arias N, Sheikh M, et al. Hepatic encephalopathy: a critical current review. Hepatol Int,2018,12(1): 135-147.
[2] de Lorenzo-Pinto A, García-Sánchez R, Lorenzo-Salinas A. Lactulose enemas in the treatment of hepatic encephalopathy. Do we help or harm? Rev Esp Enferm Dig, 2017, 109(10): 736-737.
[3] Wang Z, Chu P, Wang W. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy. Drug Des Devel Ther, 2018, 13(1): 1-11.
[4] 唐夏姣, 曾欣, 谢渭芬, 等. 利福昔明治疗和预防肝性脑病的研究进展. 中华消化杂志, 2015, 35(2): 138-141.
[5] 中华医学会消化病学分会, 中华医学会肝病学分会. 中国肝性脑病诊治共识意见(2013 年,重庆). 中华肝脏病杂志, 2013, 21(9): 641-651.
[6] Lauren S, DeLuca J, Benedict Ralph HB, et al. Symbol digit modalities test: a valid clinical trial endpoint for measuring cognition in multiple sclerosis. Multiple sclerosis. Houndmills Basingstoke Engl, 2019, 25(13): 1781-1790.
[7] Said VJ, Garcia-Trujillo E. Beyond lactulose. treatment options for hepatic encephalopathy. Gastroenterol Nurs, 2019, 42(3): 277-285.
[8] Shehata HH, Elfert AA, Abdin AA, et al. Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy. Eur J Gastroenterol Hepatol, 2018, 30(12):1476-1481.
[9] Butt NI, Butt UI, Kakar AATK, et al. Is lactulose plus rifaximin better than lactulose alone in the management of hepatic encephalopathy? J Coll Physicians Surg Pak, 2018, 28(2): 115-117.
[10] Mekky MA, Riad AR, Gaber MA, et al. Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial. Arab J Gastroenterol, 2018, 19(2): 76-79.
[11] 马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变. 实用肝脏病杂志, 2019, 22(6): 892-895.
[12] Hasan S, Datta S, Bhattacherjee S, et al. A randomized controlled trial comparing the efficacy of a combination of rifaximin and lactulose with lactulose only in the treatment of overt hepatic encephalopathy. J Assoc Physicians India, 2018, 66(1): 32-6.
[13] 孙晓. 微生态制剂联合肠内营养治疗肝性脑病患者营养学及血清指标的变化. 实用肝脏病杂志, 2017, 20(6): 777-778.
[14] Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol, 2019, 31(4): 434-450.
[15] Ahire K, Sonawale A. Comparison of rifaximin plus lactulose with the lactulose alone for the treatment of hepatic encephalopathy. J Assoc Physicians India, 2017 Aug, 65(8): 42-46.
[16] Kornerup LS, Gluud LL, Vilstrup H, et al. Update on the therapeutic management of hepatic encephalopathy. Curr Gastroenterol Rep, 2018, 20(5): 21.
[17] Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol, 2015, 13(12): 2048-2061.
[18] Zucker DM, Redulla R. Lactulose management of minimal hepatic encephalopathy: a systematic review. Gastroenterol Nurs, 2019, 42(1): 84-94.
[19] Kaji K, Takaya H, Saikawa S, et al. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol, 2017, 23(47): 8355-8366.
[20] Kang SH, Lee YB, Lee JH, et al. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Aliment Pharmacol Ther, 2017, 46(9): 845-855.